Large CAP Pharma Companies’ Performance Reviewed in Topical Report by MP Advisors Available at MarketPublishers.com

18 Jan 2017 • by Natalie Aster

LONDON – Today, the top pharma companies continue to take various measures and approaches to improve the productivity. For instance, now companies focus on selected therapy areas, M&A, consolidation in animal health, consumer healthcare and vaccines, as well as on divestment of non-core sectors and brands.

During the recent time, oncology sector has been the primary area of interest for large cap pharma companies. Moreover, the immune-oncology field is presently one of the most explosive fields in the overall biotechnology market.

Bristol-Myers’s with its Anti-PD-1 drug has recently gained the dominance in the immuno-oncology field. Furthermore, Roche (RHHBY), AstraZeneca (AZN) and Merck (MRK) are also chasing the filed.

The value of the world’s immuno-oncology drugs sector is predicted to exceed USD 40 billion in the next 10 years.

Anti-infective field remains attractive for large pharm. Roche’s in-licensing deal worth USD 1 billion and Merck acquisition of Cubist for USD 9 billion are the most prominent deals in this field.

Meantime, Biogen Idec makes focus on the development of drugs for specialty medicine like inflammatory bowel disease or multiple sclerosis, neurodegeneration like Parkinson’s or Alzheimer’s, and also rare diseases like neuropathic pain or hemophilia.

Another pharma giant, Celgene (CELG), keeps capitalizing on its strength in hematology as well as operational excellence to reach global standards of care in the sectors of oncology and also inflammation and immunology.

Topical report “Large CAP Pharma US & EU Outlook 2016: Maximizing Their Strength on Fewer Therapy Class, Personalized Medicine, Novel Target and Biosimilars for Future Growth” prepared by MP Advisors presents a comprehensive analysis of individual CAP pharma companies, identifies top drug candidates, contains pipeline analysis, sheds light on the competitive landscape and discusses the hottest issues of the important therapy areas. This report reviews the recent innovations, examines the market dynamics and factors influencing it, touches upon the regulatory issues and also points out top challenges and opportunities. Forecasts are available as well.

For other in-demand topical studies worked out by this publisher are provided at the MP Advisors page.

CONTACTS

The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com